For research use only. Not for therapeutic Use.
2OH-BNPP1 is an inhibitor of BUB1 kinase, a Ser/Thr kinase, used for the treatment of cancer.
2OH-BNPP1 (0.1-50 μM) abrogates TGFβ signaling in a dose dependent manner. 2OH-BNPP1 dose-dependently impairs the TGFβ-induced phosphorylation of proteins that mediate canonical and non-canonical TGFβ signaling in multiple cancer cell lines and normal cell lines[1].
2OH-BNPP1 (50 mg/kg) blocks TGFβ signaling in vivo, and significantly decreases abundance of phosphorylated SMAD2 in tumor-bearing mice[1].
| Catalog Number | I012884 |
| CAS Number | 833481-73-5 |
| Synonyms | 2-[(4-amino-1-tert-butylpyrazolo[3,4-d]pyrimidin-3-yl)methyl]phenol |
| Molecular Formula | C16H19N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C16H19N5O/c1-16(2,3)21-15-13(14(17)18-9-19-15)11(20-21)8-10-6-4-5-7-12(10)22/h4-7,9,22H,8H2,1-3H3,(H2,17,18,19) |
| InChIKey | LWLCFWPPMNPMOI-UHFFFAOYSA-N |
| SMILES | CC(C)(C)N1C2=NC=NC(=C2C(=N1)CC3=CC=CC=C3O)N |
| Reference | [1]. Nyati S, et al. The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci Signal. 2015 Jan 6;8(358):ra1. |
